OBJECTIVES: Elevated advanced glycation endproducts (AGEs) are implicated in diabetic complications. Methylglyoxal-derived hydroimidazolone (MG-H) is one of the most abundant AGEs in vivo. Our objective was to develop a time-saving, specific method to measure free MG-H in plasma and determine its levels in complication-free young individuals with Type 1 diabetes (T1DM). The relationship of plasma free MG-H to hemoglobin A1C (A1C) and plasma methylglyoxal levels was also determined. DESIGN AND METHODS: A solid phase extraction and liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed, and free plasma MG-H levels were measured in 40 T1DM patients (DM group), aged 6-21 years, and 11 non-diabetics (ND group), 6-22 years. Methylglyoxal was measured using LC-MS/MS and A1C by a Tosoh G7 high-performance liquid chromatograph. RESULTS: Our method showed high recovery, sensitivity and short run-time. Plasma free MG-H (nmol/L) was higher (p<0.001) in the DM group (1318+/-569; mean+/-standard deviation) as compared to the ND group (583+/-419). Within the DM group, plasma free MG-H did not correlate with plasma methylglyoxal or A1C. CONCLUSIONS: Our LC-MS/MS method to measure free MG-H in plasma may be useful for future clinical application. The increased levels of free MG-H observed in individuals with TIDM are not merely the result of short term changes in glucose or methylglyoxal, but may reflect long-term alterations to tissue proteins.
OBJECTIVES: Elevated advanced glycation endproducts (AGEs) are implicated in diabetic complications. Methylglyoxal-derived hydroimidazolone (MG-H) is one of the most abundant AGEs in vivo. Our objective was to develop a time-saving, specific method to measure free MG-H in plasma and determine its levels in complication-free young individuals with Type 1 diabetes (T1DM). The relationship of plasma free MG-H to hemoglobin A1C (A1C) and plasma methylglyoxal levels was also determined. DESIGN AND METHODS: A solid phase extraction and liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed, and free plasma MG-H levels were measured in 40 T1DM patients (DM group), aged 6-21 years, and 11 non-diabetics (ND group), 6-22 years. Methylglyoxal was measured using LC-MS/MS and A1C by a Tosoh G7 high-performance liquid chromatograph. RESULTS: Our method showed high recovery, sensitivity and short run-time. Plasma free MG-H (nmol/L) was higher (p<0.001) in the DM group (1318+/-569; mean+/-standard deviation) as compared to the ND group (583+/-419). Within the DM group, plasma free MG-H did not correlate with plasma methylglyoxal or A1C. CONCLUSIONS: Our LC-MS/MS method to measure free MG-H in plasma may be useful for future clinical application. The increased levels of free MG-H observed in individuals with TIDM are not merely the result of short term changes in glucose or methylglyoxal, but may reflect long-term alterations to tissue proteins.
Authors: Karen A Weikel; Paul Fitzgerald; Fu Shang; M Andrea Caceres; Qingning Bian; James T Handa; Alan W Stitt; Allen Taylor Journal: Invest Ophthalmol Vis Sci Date: 2012-02-02 Impact factor: 4.799
Authors: M G A van Eupen; M T Schram; H M Colhoun; N M J Hanssen; H W M Niessen; L Tarnow; H H Parving; P Rossing; C D A Stehouwer; C G Schalkwijk Journal: Diabetologia Date: 2013-04-26 Impact factor: 10.122
Authors: Marcelle G A van Eupen; Miranda T Schram; Helen M Colhoun; Jean L J M Scheijen; Coen D A Stehouwer; Casper G Schalkwijk Journal: Cardiovasc Diabetol Date: 2013-10-17 Impact factor: 9.951
Authors: Marie-Julie Nokin; Florence Durieux; Paul Peixoto; Barbara Chiavarina; Olivier Peulen; Arnaud Blomme; Andrei Turtoi; Brunella Costanza; Nicolas Smargiasso; Dominique Baiwir; Jean L Scheijen; Casper G Schalkwijk; Justine Leenders; Pascal De Tullio; Elettra Bianchi; Marc Thiry; Koji Uchida; David A Spiegel; James R Cochrane; Craig A Hutton; Edwin De Pauw; Philippe Delvenne; Dominique Belpomme; Vincent Castronovo; Akeila Bellahcène Journal: Elife Date: 2016-10-19 Impact factor: 8.140